Publications by authors named "David Adegbite"
Article Synopsis
- Pneumococcus is a significant cause of lower respiratory infections in adults, and research was conducted to understand its impact on pneumonia and other lung diseases since the emergence of SARS-CoV-2.
- A study in two Bristol hospitals included over 10,000 patients with acute lower respiratory tract diseases, revealing that 11.5% had pneumococcal infections, with higher rates among older adults.
- The study found that a substantial portion of pneumococcal cases were linked to vaccine serotypes, indicating the importance of vaccination in reducing respiratory infections in this population.
BackgroundUnderstanding the relative vaccine effectiveness (rVE) of new COVID-19 vaccine formulations against SARS-CoV-2 infection is a public health priority. A precise analysis of the rVE of monovalent and bivalent boosters given during the 2022 spring-summer and autumn-winter campaigns, respectively, in a defined population remains of interest.AimWe assessed rVE against hospitalisation for the spring-summer (fourth vs third monovalent mRNA vaccine doses) and autumn-winter (fifth BA.
View Article and Find Full Text PDFArticle Synopsis
- A study evaluated the effectiveness of the BNT162b2 mRNA vaccine in reducing severity of COVID-19, focusing on hospitalisation and related health outcomes in adults during the Delta and Omicron periods.
- In total, 935 controls and 546 COVID-19 cases were analyzed, revealing varying vaccine effectiveness against hospitalisation and other serious health indicators, with differences noted between the Delta and Omicron variants.
- The findings suggest that BNT162b2 significantly lowers the risk of severe illness from COVID-19, particularly in older adults, highlighting its importance in high-risk groups.
Background: On Dec 8, 2020, deployment of the first SARS-CoV-2 vaccination authorised for UK use (BNT162b2 mRNA vaccine) began, followed by an adenoviral vector vaccine ChAdOx1 nCoV-19 on Jan 4, 2021. Care home residents and staff, frontline health-care workers, and adults aged 80 years and older were vaccinated first. However, few data exist regarding the effectiveness of these vaccines in older people with many comorbidities.
View Article and Find Full Text PDF